Genentech sponsored a health equity symposium in partnership with the American Cancer Society and the University of Illinois Cancer Center over the weekend to underscore the need for health equity.
Amid Zantac trial setbacks, GSK touts promising oncology data at ASCO 2024
GSK results from a Phase 2 study that found Jemperli showed a 100% clinical complete response rate in patients with mismatch repair deficient locally advanced rectal cancer.
To close cancer gaps, AstraZeneca and NHL skate to where the puck is going
Encouraging developments included an opportunity to build on the blockbuster debut of GSK’s RSV vaccine and the potential return of a previously withdrawn cancer drug.
Gilead invests $320M in Arcus to increase stake to 33%
The deal, which includes an upfront commitment from AstraZeneca as well as funding and milestone payments, marks the latest sign of Big Pharma’s confidence in AI-fueled R&D.
AbbVie to acquire ADC manufacturer ImmunoGen for $10.1B in oncology play
The ImmunoGen deal, which is expected to close in the middle of 2024, is also estimated to be accretive to AbbVie’s diluted earnings per share beginning in 2027.
Gilead Oncology’s brand refresh takes back the possibilities cancer steals
Amgen Partners of Choice will comprise eight medical institutions worldwide, including the Dana-Farber Cancer Institute in Boston and Gustave Roussy in Paris.
AI Deciphered: Discovering the Potential for Marketers and Communicators